首页> 外文OA文献 >Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?
【2h】

Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?

机译:临床试验的中期结果:我们是否需要对所有临时随机临床试验结果保密?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives: Guidelines for the conduct of clinical trials emphasize the importance of keeping the interim results from the main endpoints confidential, in order to maintain the integrity of the trial and to safeguard patients' interests. However, is this essential in every situation? Materials and methods: We review the evidence for these guidelines and consider recent randomised trials that have released interim results, to assess their impact on the success of the trial. However, because the strength of opinion to keep interim results confidential is so strong, there are limited examples of such trials. Results: In the QUARTZ trial (which is assessing the value of whole brain radiotherapy in patients with brain metastases from non-small cell lung cancer) the decision to release interim results was taken in response to threatened closure due to poor accrual, whereas in the GRIT trial (which compared two obstetric strategies for the delivery of growth retarded pre-term fetuses) the regular release of interim results was pre-planned. Nevertheless there are a number of common factors between these two trials. In particular, the trial treatments were already in wide use, with no reliable randomised evidence on which treatment should be used for which patients, and there was diverse clinical opinion, which meant that accrual was likely to be challenging. In a situation where a quarter to a third of trials do not accrue their required number of patients, the QUARTZ trial continues to accrue patients, and the GRIT trial successfully accrued its target of nearly 600 babies. Conclusions: This article therefore argues that there is a need to re-consider whether it is always essential to keep the interim results of randomized clinical trials confidential, and suggests some criteria that may help groups planning or running challenging trials decide whether releasing interim results would be a useful strategy. © 2014 The Authors.
机译:目标:进行临床试验的指南强调了对主要终点的中期结果进行保密的重要性,以保持试验的完整性并维护患者的利益。但是,这在每种情况下都至关重要吗?材料和方法:我们审查了这些指南的证据,并考虑了近期发布临时结果的随机试验,以评估其对试验成功的影响。但是,由于对中期结果保密的意见非常强烈,因此此类审判的例子有限。结果:在QUARTZ试验中(该试验评估了全脑放疗对非小细胞肺癌脑转移患者的价值),决定发布中期结果是为了应对因应计较差而导致的封闭性关闭,而在计划进行GRIT试验(比较了两种产科策略来治疗发育迟缓的早产胎儿),定期发布中期结果。然而,这两个试验之间存在许多共同因素。特别是,试验治疗方法已经广泛使用,没有可靠的随机证据表明应针对哪些患者使用哪种治疗方法,并且临床观点也多种多样,这意味着应计费用可能具有挑战性。在四分之一至三分之一的试验未能达到所需患者人数的情况下,QUARTZ试验仍在继续增加患者,而GRIT试验成功地达到了将近600名婴儿的目标。结论:因此,本文认为,有必要重新考虑对随机临床试验的中期结果保密是否总是必不可少的,并提出一些准则,可能有助于小组计划或进行具有挑战性的试验,以决定是否发布中期结果是一个有用的策略。 ©2014作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号